Demise of the life science company begins
Article Abstract:
Basel, Switzerland-based Novartis and London, UK-based AstraZeneca recently announced that they plan to spin off and merge their agrochemical divisions. The company formed by this move will be called Syngenta.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Biotech companies adapt to big pharma mergers
Article Abstract:
Biotechnology companies in the U.S. and Europe are drawing up licensing contracts to protect already-existing research partnerships in light of the increasing trend of mergers among pharmaceutical companies.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Genzyme acquires Cell Genesys
Article Abstract:
In October, Genzyme (Cambridge, MA) paid $350m to acquire Cell Genesys (Foster City, CA), and its 500+ patents in gene and protein therapy, along with various drugs in trial, including cancer drugs.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Biocompatibles International. Biocompatibles heads for the heart
- Abstracts: Information technology as competitive advantage: the role of human, business, and technology resources. Competitive advantage: logical and philosophical considerations
- Abstracts: European equities cheap - but not nasty. European alliance. The European domino effect
- Abstracts: The end of the human touch? Playing the field
- Abstracts: A genetic heritage betrayed or empowered? Johnson & Johnson acquires Centocor. Scientists avert new GMO crisis